<DOC>
	<DOCNO>NCT02515799</DOCNO>
	<brief_summary>The purpose study evaluate mucolytic activity Tacholiquine® compare saline ( 0.9 % ) chronic bronchitis patient . Lung function parameter , biomarker profile sputum serum , clinical symptom standardize questionnaire [ COPD activity index ( CAT ) , Baseline Dyspnea Index ( BDI ) &amp; Transition Dyspnea Index ( TDI ) St. George 's Respiratory Questionnaire ( SGRQ ) ] evaluate response Tacholiquine® vs. saline chronic bronchitis patient .</brief_summary>
	<brief_title>Mucolytic Effectiveness Tacholiquine ® Chronic Bronchitis</brief_title>
	<detailed_description>The aim study compare Tacholiquine ® saline ( 0.9 % ) regard ability promote discharge mucus respiratory passages patient chronic bronchitis ( COPD ) . Alleviated discharge mucus ease breathing , improve subjective wellbeing , reduce inflammation air passage improve lung function . Determine magnitude effect Tacholiquine ® compare saline ( 0.9 % ) chronic bronchitis patient . Lung function parameter , biomarker profile sputum serum , clinical symptom quality life standardize questionnaire [ COPD activity index ( CAT ) , Baseline Dyspnea Index ( BDI ) &amp; Transition Dyspnea Index ( TDI ) , St George 's respiratory Quality Life Questionnaire ] evaluate response Tacholiquine ® vs. saline day one end treatment .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Expectorants</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedure . 2 . Female male subject age 4085 year inclusive Visit 1 . 3 . Documented history COPD postbronchodilator FEV1/FVC &lt; 0.70 postbronchodilator FEV1 &lt; 80 % predict normal value screening ( spirometry use criterion assessment ) . 4 . Current smoker exsmoker tobacco history ≥10 packyears ( 1 pack year = 20 cigarette smoke per day 1 year ) . 5 . Women childbearing potential ( WOCBP ) must use highly effective form birth control ( confirm Investigator ) . − Women &gt; 50 year old would consider postmenopausal 6 . At least CAT value &gt; 10 Visit 1 . 7 . Presence chronic cough sputum production either `` several day per week '' `` almost every day '' 1 . Clinically important pulmonary disease COPD ( e.g . active lung infection , clinically significant bronchiectasis , pulmonary fibrosis , cystic fibrosis , hypoventilation syndrome associate obesity , lung cancer , alpha 1 antitrypsin deficiency primary ciliary dyskinesia ) another diagnose pulmonary systemic disease associate elevated peripheral eosinophil count ( e.g . allergic bronchopulmonary aspergillosis/mycosis , ChurgStrauss syndrome , hypereosinophilic syndrome ) . 2 . Any disorder , include , limited , cardiovascular , gastrointestinal , hepatic , renal , neurological , musculoskeletal , infectious , endocrine , metabolic , haematological , psychiatric , major physical impairment stable opinion Investigator could : Affect safety subject throughout study Influence finding study interpretation Impede subject 's ability complete entire duration study 3 . Documented Unstable ischemic heart disease , arrhythmia , cardiomyopathy , heart failure , renal failure , uncontrolled hypertension define Investigator , relevant cardiovascular disorder judge Investigator Investigator 's judgment may put patient risk negatively affect outcome study . 4 . Treatment systemic corticosteroid and/or antibiotic , and/or hospitalization COPD exacerbation within 4 week prior ( Visit 1 ) . 5 . Acute upper low respiratory infection require antibiotic antiviral medication within 4 week prior ( Visit 1 ) . 6 . Pneumonia within 4 week prior ( Visit 1 ) , base last day antibiotic treatment hospitalization date , whatever occur later . The subject rescreened exclusion criterion meet . 7 . History anaphylaxis Tacholiquine® . 8 . Long term oxygen therapy ( LTOT ) define need oxygen &gt; 4L 02 flow sign and/or symptom cor pulmonale , right ventricular failure evidence echocardiogram pulmonary artery catheterization moderate severe pulmonary hypertension . In order admit trial subject LTOT ambulatory able attend clinic visit . 9 . Any clinically significant abnormal finding physical examination , vital sign , hematology , urinalysis Visit 1 , , opinion Investigator , may put subject risk his/her participation study , may influence result study , subject 's ability complete entire duration study . 10 . Use immunosuppressive medication , include rectal corticosteroid , high potency topical corticosteroid systemic steroid within 28 day prior ( Visit 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>